Lymphoma

CHIP Associated with Poorer Outcomes in Lymphoma

CHIP Associated with Poorer Outcomes in Lymphoma

By

Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

By

Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure

ASH 2018: Practice-Changing Findings on Treatment of Lymphoma

ASH 2018: Practice-Changing Findings on Treatment of Lymphoma

John Burke, MD, discusses the latest research at ASH 2018.

Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma

Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma

By

US FDA recently approved rituximab biosimilar as monotherapy and in combination with chemotherapy.

Long-Term Data Show Low Risk of Second Primary Malignancy, Transformation in WM

Long-Term Data Show Low Risk of Second Primary Malignancy, Transformation in WM

By

Study shows risk of second primary malignancy or transformation to lymphoma is low.

Yescarta in the Real-World Setting: How Did the Results Compare With ZUMA-1 Outcomes?

Yescarta in the Real-World Setting: How Did the Results Compare With ZUMA-1 Outcomes?

By

Inferior patient outcomes from treatment with axi-cel were linked to poor performance status and increased tumor bulk in patients.

CD20xCD3 Bispecific Antibody REGN1979 in B-cell Non-Hodgkin Lymphoma

CD20xCD3 Bispecific Antibody REGN1979 in B-cell Non-Hodgkin Lymphoma

Rajat Bannerji, MD, PhD, discusses his findings at the ASH 2018 meeting.

A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL

A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL

By

Checkpoint-based therapies may sensitize patients to subsequent therapies.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Next-Generation Sequencing Helped Identify Pathways for Transformation of WM to DLBCL

Next-Generation Sequencing Helped Identify Pathways for Transformation of WM to DLBCL

By

IGHV analysis demonstrated that DLBCL tissue was clonally related to the antecedent WM clone.

New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma

New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma

By

The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Tackling EBV-Associated Lymphoma: Early Research Finds Overall Survival Benefit After Donor Transplants

Tackling EBV-Associated Lymphoma: Early Research Finds Overall Survival Benefit After Donor Transplants

By

Use of experimental T cells that target Epstein-Barr virus proteins in relapsed or refractory lymphoma may improve overall survival.

Younger Women May Have Better Chance at Ovarian Function Recovery After Treatment for Hodgkin Lymphoma

Younger Women May Have Better Chance at Ovarian Function Recovery After Treatment for Hodgkin Lymphoma

By

Women aged 35 years or older diagnosed with Hodgkin lymphoma should discuss fertility preservation prior to treatment.

Bortezomib-Based Frontline Therapy Boosts Survival in Mantle Cell Lymphoma

Bortezomib-Based Frontline Therapy Boosts Survival in Mantle Cell Lymphoma

By

Replacement of vincristine with bortezomib in R-CHOP regimen significantly improved median OS in previously untreated patients with mantle cell lymphoma.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

By

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

By

Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

By

Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

All CAR Signaling Domains in Lymphoma Are Not Created Equal

All CAR Signaling Domains in Lymphoma Are Not Created Equal

By

Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

By

Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Liquid Biopsy May Predict Response to Therapy in Diffuse Large B-Cell Lymphoma

Liquid Biopsy May Predict Response to Therapy in Diffuse Large B-Cell Lymphoma

By

Circulating tumor DNA levels measured as early as 3 weeks post-therapy may provide clues about long-term outcomes in this lymphoma subtype.

Obinutuzumab in Follicular Lymphoma

Obinutuzumab in Follicular Lymphoma

By

Many patients with follicular lymphoma will be asymptomatic and present with variable cervical, axillary, and inguinal adenopathy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs